North America Leads Global Drug Use, UN Report Shows

North America leads the world in the use of cannabis, opioids, and amphetamines, according to the United Nations World Drug Report published in June 2026 and reported by ZeroHedge. North Americans between the ages of 15 and 64 were 75 percent to 90 percent more likely to have consumed these drugs in 2024 than residents of second-ranked Oceania, the report states. The findings highlight regional variations in global drug use patterns and the evolving nature of synthetic drug markets.

Key takeaways
North America had the highest prevalence of cannabis, opioid, and amphetamine use in 2024, according to the UN World Drug Report.
331 million people worldwide consumed drugs in 2024, equivalent to 6.2 percent of the global population.
Synthetic opioids like fentanyl were detected in more than half of all U.S. drug deaths as of 2025.
Myanmar has emerged as a major producer of amphetamines and opiates as Afghanistan's opium production decreased.

Table of Contents
What the UN report confirmed
Regional drug use patterns
Synthetic opioid market shift
Global amphetamine production changes
Why these trends matter
What to watch next

What the UN report confirmed

The UN World Drug Report confirmed that 331 million people worldwide consumed drugs in 2024, equivalent to 6.2 percent of the global population. North Americans between the ages of 15 and 64 were 75 percent to 90 percent more likely to have consumed cannabis, opioids, and amphetamines in 2024 than residents of Oceania, which ranked second. The report attributed broader marijuana legalization in the United States as a driver of consumption in the region. Despite high opioid use, overdose deaths in the United States have come down from their peaks in the last couple of years, according to the source context.

The odds of dying of an accidental opioid overdose in the United States was still higher in 2024 than the risk of losing one's life due to a car crash or suicide, the report stated. Marijuana remains the most common drug by far globally, but the UN observed a change in the second-placed market for opioids, where synthetic opioids have been taking on an increasingly larger role. The report also noted that drug manufacturers are using innovation as a tool to skirt regulations and avoid detection, leading to the type of drugs found in seizures continuously evolving and increasing in variety.

Regional drug use patterns

Oceania had the highest prevalence of cocaine and ecstasy use, mainly in Australia and New Zealand, according to the UN report. South America saw a relatively high use of cocaine and amphetamines, while opioids were more widespread in Asia than in South America or Europe. The regional variations reflect differences in drug production, trafficking routes, regulatory environments, and cultural factors that influence consumption patterns. North America's leadership in cannabis, opioid, and amphetamine use was 75 percent to 90 percent higher than Oceania's prevalence, making it the most affected region across multiple drug categories.

The report's findings highlight how drug markets are shaped by both supply-side factors such as production and trafficking, and demand-side factors including legalization policies, prescription practices, and public health responses. For readers following broader general market briefs , these regional patterns can help frame the wider context of public health policy and international regulatory coordination. The data also underscores the importance of monitoring how changes in one region's drug production can influence consumption patterns globally.

Synthetic opioid market shift

The UN report observed a change in the opioid market, with synthetic opioids taking on an increasingly larger role in response to the crackdown on opium poppy production in Afghanistan. Strong synthetic opioids like fentanyl have been a major driver in the American overdose epidemic and as of 2025 were still detected in more than half of all U.S. drug deaths. The shift from plant-based opiates to synthetic opioids represents a significant change in the drug supply chain, with implications for public health, law enforcement, and international drug policy.

Synthetic opioids are often more potent and easier to produce in clandestine laboratories than traditional opiates derived from poppy cultivation. This shift has made the drug supply more unpredictable and dangerous, as users may not know the exact composition or potency of the substances they consume. The report's findings suggest that efforts to reduce opium production in one region can lead to unintended consequences in the form of increased synthetic drug manufacturing elsewhere. The ongoing presence of fentanyl in more than half of U.S. drug deaths as of 2025 indicates that the synthetic opioid crisis remains a persistent public health challenge.

Global amphetamine production changes

Amphetamines, with a global annual use prevalence of 0.6 percent, are the world's third biggest drug and have seen their market globalize, according to the UN report. Myanmar has emerged as a major producer country for amphetamines consumed globally and has also picked up opiate production as Afghanistan's output decreased. This shift in production geography reflects how drug manufacturing can adapt to enforcement actions and market demand, with new producer countries filling gaps left by crackdowns in traditional source regions.

The globalization of the amphetamine market means that production, trafficking, and consumption are increasingly interconnected across regions. Myanmar's emergence as a major producer highlights the challenges of international drug control, as enforcement efforts in one country can lead to production shifting to areas with weaker regulatory oversight or governance challenges. The report's findings suggest that effective drug policy requires coordinated international efforts that address both supply and demand, as well as the underlying economic and social factors that enable drug production and trafficking.

Why these trends matter

The UN World Drug Report's findings matter because they provide a comprehensive view of global drug use patterns and the evolving nature of drug markets. For policymakers, public health officials, and law enforcement agencies, understanding regional variations in drug use and the shift toward synthetic drugs is essential for designing effective interventions. The report's data on North America's leadership in cannabis, opioid, and amphetamine use, combined with the ongoing presence of fentanyl in U.S. drug deaths, underscores the need for sustained public health responses and harm reduction strategies.

The shift from plant-based drugs to synthetic substances also has implications for international drug control efforts. Traditional enforcement strategies focused on crop eradication and interdiction may be less effective against synthetic drugs that can be produced in small, mobile laboratories. The report's observation that drug manufacturers are using innovation to skirt regulations and avoid detection suggests that regulatory frameworks and enforcement tactics must also evolve. For readers interested in public health policy, international relations, and regulatory trends, these findings provide important context for understanding the challenges and opportunities in addressing global drug use.

What to watch next

Readers should watch for future UN World Drug Reports and updates from national public health agencies on drug use trends, overdose statistics, and enforcement actions. The report's findings on synthetic opioids and the globalization of amphetamine production suggest that monitoring changes in drug manufacturing locations and trafficking routes will be important for understanding future market dynamics. Any updates on Afghanistan's opium production, Myanmar's role as a drug producer, and the effectiveness of harm reduction programs in North America and other regions will provide additional context.

Future disclosures on the effectiveness of marijuana legalization policies in the United States, the impact of fentanyl detection and interdiction efforts, and international cooperation on drug control will also be relevant. The report's observation that drug manufacturers are continuously innovating to avoid detection suggests that regulatory agencies and law enforcement will need to adapt their strategies. Readers may also watch for research on the public health and economic impacts of drug use, as well as policy debates on harm reduction, treatment access, and the balance between enforcement and public health approaches.

Read original source